Chondroitin sulfate in the treatment of osteoarthritis
DOI: 10.32364/2587-6821-2022-6-3-148-152
S.P. Yakupova., E.A. Fedorova
Kazan State Medical University, Kazan, Russian Federation
Osteoarthritis (OA) is a common disease in the practice of doctors of various specialties. Leading international organizations regularly update recommendations for the treatment of patients with this disease. The viewpoints of experts differ concerning various interventions. The article issues the use of a drug group — Symptomatic Slow-Acting Drug in Osteoarthritis (SYSADOA), such as glucosamine and chondroitin sulfate (CS). To date, data on the efficacy and good tolerability of these drugs have been accumulating, which is important due to the significant comorbidity in patients with OA. The results of numerous studies reviewed by the authors have suggested a possible mechanism of analgesic and anti-inflammatory action of chondroitin sulfate (CS). In the leading international and national recommendations, CS is included in the treatment regimens of patients with OA, with the clarification that the prescription form has an advantage. The recommendations of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, (ESCEO) in 2019 strongly recommended the use of high-quality CS as a long-term background treatment.
Keywords: osteoarthritis, recommendations, symptomatic slow-acting drug, chondroitin sulfate.
For citation: Yakupova S.P., Fedorova E.A. Chondroitin sulfate in the treatment of osteoarthritis. Russian Medical Inquiry. 2022;6(3):148–152 (in Russ.). DOI: 10.32364/2587-6821-2022-6-3-148-152.
Acknowledgements
The technical edition is supported by LLC "Pierre Fabre".
About the authors:
Svetlana P. Yakupova — C. Sc. (Med.), Associate Professor of the Department of Hospital Therapy, Kazan State Medical University; 49, Butlerov str., Kazan, 420012, Russian Federation; ORCID iD 0000-0002-8590-4839.
Elvina A. Fedorova — 6th year student of the Medical Faculty, Kazan State Medical University; 49, Butlerov str., Kazan, 420012, Russian Federation; ORCID iD 0000-0002-6837-5728.
Contact information: Svetlana P. Yakupova, e-mail: YakupovaSP@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 01.02.2022.
Revised 25.02.2022.
Accepted 24.03.2022.
2. Bruyère O., Honvo G., Veronese N. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337–350. DOI: 10.1016/j.semarthrit.2019.04.008.
3. Bannuru R.R., Osani M.C., Vaysbrot E.E. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578–1589. DOI: 10.1016/j.joca.2019.06.011.
4. Kolasinski S.L., Neogi T., Hochberg M.C. et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020;72(2):220–233. DOI: 10.1002/art.41142.
5. NICE. Osteoarthritis: care and management. (Electronic resource.) URL: https://www.nice.org.uk/guidance/CG177 (access date: 13.02.2022).
6. Management of Osteoarthritis of the Knee (Non-Arthroplasty) Evidence-Based Clinical Practice Guideline. (Electronic resource.) https://www.aaos.org/globalassets/quality-and-practice-resources/osteoarthritis-of-the-knee/oak3cpg.pdf (access date: 13.02.2022).
7. Клинические рекомендации. Коксартроз. 2021. (Электронный ресурс.) URL: https://cr.minzdrav.gov.ru/recomend/666_1 (дата обращения: 13.02.2022). [Clinical guidelines. Coxarthrosis. 2021. (Electronic resource.) URL: https://cr.minzdrav.gov.ru/recomend/666_1 (access date: 13.02.2022) (in Russ.)].
8. Клинические рекомендации. Гонартроз. 2021. (Электронный ресурс.) URL: https://cr.minzdrav.gov.ru/schema/667_1 (дата обращения: 13.02.2022). [Clinical guidelines. Gonarthrosis. 2021. (Electronic resource.) URL: https://cr.minzdrav.gov.ru/schema/667_1 (access date: 13.02.2022) (in Russ)].
9. Bichsel D., Liechti F.D., Schlapbach J.M., Wertli M.M. Cross-sectional Analysis of Recommendations for the Treatment of Hip and Knee Osteoarthritis in Clinical Guidelines. Arch Phys Med Rehabil. 2022;103(3):559–569.e5. DOI: 10.1016/j.apmr.2021.07.801.
10. Arden N.K., Perry T.A., Bannuru R.R. et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nat Rev Rheumatol. 2021;17(1):59–66. DOI: 10.1038/s41584-020-00523-9.
11. Лила А.М., Алексеева Л.И., Телышев К.А. Современные подходы к фенотипированию остеоартрита. Современная ревматология. 2019;13(2):4–8. DOI: 10.14412/1996-7012-2019-2-4-8. [Lila A.M., Alekseeva L.I., Telyshev K.A. Current approaches to osteoarthritis phenotyping. Sovremennaya Revmatologiya. 2019;13(2):4–8 (in Russ.)]. DOI: 10.14412/1996-7012-2019-2-4-8.
12. McAlindon T.E., Bannuru R.R., Sullivan M.C. et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363–388. DOI: 10.1016/j.joca.2014.01.003.
13. Dell'Isola A., Allan R., Smith S.L. et al. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC Musculoskelet Disord. 2016;17(1):425. DOI: 10.1186/s12891-016-1286-2.
14. Roman-Blas J.A., Mendoza-Torres L.A., Largo R., Herrero-Beaumont G. Setting up distinctive outcome measures for each osteoarthritis phenotype. Ther Adv Musculoskelet Dis. 2020;12:1759720X20937966. DOI: 10.1177/1759720X20937966.
15. Swain S., Sarmanova A., Coupland C. et al. Comorbidities in Osteoarthritis: A Systematic Review and Meta-Analysis of Observational Studies. Arthritis Care Res (Hoboken). 2020;72(7):991–1000. DOI: 10.1002/acr.24008.
16. Ronca F., Palmieri L., Panicucci P., Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 1998;6 Suppl A:14–21. DOI: 10.1016/s1063-4584(98)80006-x.
17. Tan B.H., Ahemad N., Pan Y. et al. In vitro inhibitory effects of glucosamine, chondroitin and diacerein on human hepatic CYP2D6. Drug Metab Pers Ther. 2021. DOI: 10.1515/dmdi-2020-0182.
18. Stellavato A., Restaino O.F., Vassallo V. et al. Comparative Analyses of Pharmaceuticals or Food Supplements Containing Chondroitin Sulfate: Are Their Bioactivities Equivalent? Adv Ther. 2019;36(11):3221–3237. DOI: 10.1007/s12325-019-01064-8.
19. Алексеева Л.И., Беневоленская Л.И., Насонов Е.Л. и др. Структум (хондроитин сульфат) — новое средство для лечения остеоартроза. Терапевтический архив. 1999;5:51–53. [Alekseyeva L.I., Benevolenskaya L.I., Nasonov Ye.L. et al. Structum (chondroitin sulfate) — a new drug for the treatment of osteoarthritis. Terapevticheskiy arkhiv. 1999;5:51–53 (in Russ.)].
20. Singh J.A., Noorbaloochi S., MacDonald R., Maxwell L.J. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015;1:CD005614. DOI: 10.1002/14651858.CD005614.pub2.
21. Reginster J.Y., Dudler J., Blicharski T., Pavelka K. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis. 2017;76(9):1537–1543. DOI: 10.1136/annrheumdis-2016-210860.
22. Stellavato A., Restaino O.F., Vassallo V. et al. Chondroitin Sulfate in USA Dietary Supplements in Comparison to Pharma Grade Products: Analytical Fingerprint and Potential Anti-Inflammatory Effect on Human Osteoartritic Chondrocytes and Synoviocytes. Pharmaceutics. 2021;13(5):737. DOI: 10.3390/pharmaceutics13050737.
23. Schneider H., Maheu E., Cucherat M. Symptom-modifying effect of chondroitin sulfate in knee osteoarthritis: a meta-analysis of randomized placebo-controlled trials performed with structum(®). Open Rheumatol J. 2012;6:183–189. DOI: 10.2174/1874312901206010183.
24. Hochberg M.C. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage. 2010;18 Suppl 1:S28–31. DOI: 10.1016/j.joca.2010.02.016.
25. Kloppenburg M., Kroon F.P., Blanco F.J. et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019;78(1):16–24. DOI: 10.1136/annrheumdis-2018-213826.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
